Increase in outflow facility with unoprostone treatment in ocular hypertensive patients

Carol B Toris, Guilin Zhan, Carl B. Camras

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: To determine the mechanism by which 0.15% unoprostone isopropyl reduces intraocular pressure (IOP) by studying 33 patients with ocular hypertension or primary open-angle glaucoma. Methods: At baseline, IOP was determined by pneumatonometry, aqueous flow and outflow facility by fluorophotometry, episcleral venous pressure by venomanometry, and uveoscleral outflow by mathematical calculation. Unoprostone was administered to one eye and placebo to the fellow eye of each patient twice daily in a randomized masked fashion. In patients who demonstrated an IOP reduction of 3 mm Hg or more in either eye on day 5±1 (n=29), determinations were repeated on that day and on day 28±2. Treated eyes were compared with control eyes, and treatment days were compared with baseline by paired t tests. Results: Compared with baseline, unoprostone significantly (P<.001) reduced IOP by a mean±SEM of 5.6±0.4 mm Hg and 4.8±0.6 mm Hg on days 5 and 28, respectively. The change from baseline with unoprostone was significantly (P<.001) greater than with placebo by 2.8±0.4 mm Hg on day 5 and by 3.2±0.5 mm Hg on day 28. Compared with baseline, unoprostone significantly (P≤.001) increased outflow facility by 0.05±0.01 and 0.08±0.02 μL·min-1·mm Hg-1 on days 5 and 28, respectively. The baseline-adjusted between-treatment differences were significant (P≤.04) on day 28 (0.06±0.02 μL·min -1·mm Hg-1). Other measures were not different from placebo. Conclusion: In responsive patients, unoprostone decreased IOP by increasing outflow facility.

Original languageEnglish (US)
Pages (from-to)1782-1787
Number of pages6
JournalArchives of Ophthalmology
Volume122
Issue number12
DOIs
StatePublished - Dec 1 2004

Fingerprint

Intraocular Pressure
Placebos
Fluorophotometry
Therapeutics
Ocular Hypertension
Venous Pressure

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Increase in outflow facility with unoprostone treatment in ocular hypertensive patients. / Toris, Carol B; Zhan, Guilin; Camras, Carl B.

In: Archives of Ophthalmology, Vol. 122, No. 12, 01.12.2004, p. 1782-1787.

Research output: Contribution to journalArticle

@article{38ed12ab6adc40818ecc520ca2f940d5,
title = "Increase in outflow facility with unoprostone treatment in ocular hypertensive patients",
abstract = "Objective: To determine the mechanism by which 0.15{\%} unoprostone isopropyl reduces intraocular pressure (IOP) by studying 33 patients with ocular hypertension or primary open-angle glaucoma. Methods: At baseline, IOP was determined by pneumatonometry, aqueous flow and outflow facility by fluorophotometry, episcleral venous pressure by venomanometry, and uveoscleral outflow by mathematical calculation. Unoprostone was administered to one eye and placebo to the fellow eye of each patient twice daily in a randomized masked fashion. In patients who demonstrated an IOP reduction of 3 mm Hg or more in either eye on day 5±1 (n=29), determinations were repeated on that day and on day 28±2. Treated eyes were compared with control eyes, and treatment days were compared with baseline by paired t tests. Results: Compared with baseline, unoprostone significantly (P<.001) reduced IOP by a mean±SEM of 5.6±0.4 mm Hg and 4.8±0.6 mm Hg on days 5 and 28, respectively. The change from baseline with unoprostone was significantly (P<.001) greater than with placebo by 2.8±0.4 mm Hg on day 5 and by 3.2±0.5 mm Hg on day 28. Compared with baseline, unoprostone significantly (P≤.001) increased outflow facility by 0.05±0.01 and 0.08±0.02 μL·min-1·mm Hg-1 on days 5 and 28, respectively. The baseline-adjusted between-treatment differences were significant (P≤.04) on day 28 (0.06±0.02 μL·min -1·mm Hg-1). Other measures were not different from placebo. Conclusion: In responsive patients, unoprostone decreased IOP by increasing outflow facility.",
author = "Toris, {Carol B} and Guilin Zhan and Camras, {Carl B.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1001/archopht.122.12.1782",
language = "English (US)",
volume = "122",
pages = "1782--1787",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Increase in outflow facility with unoprostone treatment in ocular hypertensive patients

AU - Toris, Carol B

AU - Zhan, Guilin

AU - Camras, Carl B.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Objective: To determine the mechanism by which 0.15% unoprostone isopropyl reduces intraocular pressure (IOP) by studying 33 patients with ocular hypertension or primary open-angle glaucoma. Methods: At baseline, IOP was determined by pneumatonometry, aqueous flow and outflow facility by fluorophotometry, episcleral venous pressure by venomanometry, and uveoscleral outflow by mathematical calculation. Unoprostone was administered to one eye and placebo to the fellow eye of each patient twice daily in a randomized masked fashion. In patients who demonstrated an IOP reduction of 3 mm Hg or more in either eye on day 5±1 (n=29), determinations were repeated on that day and on day 28±2. Treated eyes were compared with control eyes, and treatment days were compared with baseline by paired t tests. Results: Compared with baseline, unoprostone significantly (P<.001) reduced IOP by a mean±SEM of 5.6±0.4 mm Hg and 4.8±0.6 mm Hg on days 5 and 28, respectively. The change from baseline with unoprostone was significantly (P<.001) greater than with placebo by 2.8±0.4 mm Hg on day 5 and by 3.2±0.5 mm Hg on day 28. Compared with baseline, unoprostone significantly (P≤.001) increased outflow facility by 0.05±0.01 and 0.08±0.02 μL·min-1·mm Hg-1 on days 5 and 28, respectively. The baseline-adjusted between-treatment differences were significant (P≤.04) on day 28 (0.06±0.02 μL·min -1·mm Hg-1). Other measures were not different from placebo. Conclusion: In responsive patients, unoprostone decreased IOP by increasing outflow facility.

AB - Objective: To determine the mechanism by which 0.15% unoprostone isopropyl reduces intraocular pressure (IOP) by studying 33 patients with ocular hypertension or primary open-angle glaucoma. Methods: At baseline, IOP was determined by pneumatonometry, aqueous flow and outflow facility by fluorophotometry, episcleral venous pressure by venomanometry, and uveoscleral outflow by mathematical calculation. Unoprostone was administered to one eye and placebo to the fellow eye of each patient twice daily in a randomized masked fashion. In patients who demonstrated an IOP reduction of 3 mm Hg or more in either eye on day 5±1 (n=29), determinations were repeated on that day and on day 28±2. Treated eyes were compared with control eyes, and treatment days were compared with baseline by paired t tests. Results: Compared with baseline, unoprostone significantly (P<.001) reduced IOP by a mean±SEM of 5.6±0.4 mm Hg and 4.8±0.6 mm Hg on days 5 and 28, respectively. The change from baseline with unoprostone was significantly (P<.001) greater than with placebo by 2.8±0.4 mm Hg on day 5 and by 3.2±0.5 mm Hg on day 28. Compared with baseline, unoprostone significantly (P≤.001) increased outflow facility by 0.05±0.01 and 0.08±0.02 μL·min-1·mm Hg-1 on days 5 and 28, respectively. The baseline-adjusted between-treatment differences were significant (P≤.04) on day 28 (0.06±0.02 μL·min -1·mm Hg-1). Other measures were not different from placebo. Conclusion: In responsive patients, unoprostone decreased IOP by increasing outflow facility.

UR - http://www.scopus.com/inward/record.url?scp=10044229247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044229247&partnerID=8YFLogxK

U2 - 10.1001/archopht.122.12.1782

DO - 10.1001/archopht.122.12.1782

M3 - Article

C2 - 15596580

AN - SCOPUS:10044229247

VL - 122

SP - 1782

EP - 1787

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 12

ER -